Patricia Defechereux, PhD
Scientific Project Manager
Business Service Ctr
Chancellor/EVC/FAS

Publications (24)

Top publication keywords:
Medication AdherenceEmtricitabineHIV InfectionsHIV AntibodiesDrug MonitoringHomosexuality, MaleAnti-HIV AgentsHIV-1Endogenous RetrovirusesTenofovirPre-Exposure ProphylaxisSeroconversionTransgender PersonsPoint-of-Care TestingDepression

• Feasibility and staff acceptability of implementing Xpert HIV-1 viral load point-of-care testing: a pilot study in San Francisco.
  BMC infectious diseases 2025 Moore K, Tourneau NL, Alvarez J, Rodriguez S, Broussard J, Crouch PC, Roman J, Defechereux P, Bena J, Koester KA, Moran L, Pilcher C, Grant R, Christopoulos KA
• Suppressed HIV antibody responses following exposure to antiretrovirals-evidence from PrEP randomized trials and early antiretroviral treatment initiation studies.
  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2024 Avelino-Silva VI, Stone M, Bakkour S, Di Germanio C, Schmidt M, Conway AL, Wright D, Grebe E, Custer B, Kleinman SH, Deng X, Lingappa JR, Defechereux P, Mehrotra M, Grant RM, Vasan S, Facente S, …
• HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing.
  Viruses 2023 Lyons DE, Kumar P, Roan NR, Defechereux PA, Feschotte C, Lange UC, Murthy N, Sameshima P, Verdin E, Ake JA, Parsons MS, Nath A, Gianella S, Smith DM, Kallas EG, Villa TJ, Strange R, Mwesigwa B, Furler…
• Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV, O'Neal J, Yager J, Bhasin S, Sevelius J, Deutsch MB
• Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Spinelli MA, Lowery B, Shuford JA, Spindler J, Kearney MF, McFarlane JR, McDonald C, Okochi H, Phung N, Kuncze K, Jee K, Johannessen D, Anderson PL, Smith DK, Defechereux P, Grant RM, Gandhi M

Show all (19 more) Hide

• Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations.
  Journal of acquired immune deficiency syndromes (1999) 2020 Spinelli MA, Rodrigues WC, Wang G, Vincent M, Glidden DV, Okochi H, Stalter R, Defechereux P, Deutsch M, Grant RM, Ngure K, Mugo NR, Baeten JM, Gandhi M, Partners PrEP Study Team
• HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.
  AIDS (London, England) 2020 Ascher SB, Scherzer R, Estrella MM, Shigenaga J, Spaulding KA, Glidden DV, Mehrotra ML, Defechereux P, Gandhi M, Grant RM, Shlipak MG, Jotwani V
• Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.
  AIDS research and human retroviruses 2019 Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM
• Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function.
  Journal of acquired immune deficiency syndromes (1999) 2019 Hojilla JC, Satre DD, Glidden DV, McMahan VM, Gandhi M, Defechereux P, Guanira JV, Mehrotra M, Grant RM, Carrico AW
• Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project.
  AIDS (London, England) 2019 Spinelli MA, Glidden DV, Rodrigues WC, Wang G, Vincent M, Okochi H, Kuncze K, Mehrotra M, Defechereux P, Buchbinder SP, Grant RM, Gandhi M
• Identification of hepatitis B virus genotype I in Thailand.
  Journal of medical virology 2018 Holzmayer V, Hance R, Defechereux P, Grant R, Kuhns MC, Cloherty G, Rodgers MA
• Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.
  AIDS and behavior 2018 Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P, La Mar M, Beckham SW, Hammond P, Margolis D, Murray M
• The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men.
  AIDS and behavior 2018 Mehrotra ML, Rivet Amico K, McMahan V, Glidden DV, Defechereux P, Guanira JV, Grant RM
• Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
  Journal of acquired immune deficiency syndromes (1999) 2018 Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG
• Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).
  AIDS and behavior 2016 Defechereux PA, Mehrotra M, Liu AY, McMahan VM, Glidden DV, Mayer KH, Vargas L, Amico KR, Chodacki P, Fernandez T, Avelino-Silva VI, Burns D, Grant RM, iPrEx Study Team
• The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study.
  AIDS and behavior 2016 Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, Mayer KH, Veloso VG, Bekker LG, Avelino-Silva VI, Schechter M, Grant RM
• Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation.
  The Journal of infectious diseases 2015 Kuebler PJ, Mehrotra ML, Shaw BI, Leadabrand KS, Milush JM, York VA, Defechereux P, Grant RM, Kallás EG, Nixon DF
• Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.
  The Journal of infectious diseases 2015 Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, Guanira JV, Grinsztejn B, Chariyalertsak S, Bekker LG, Grant RM, iPrEx Study Team
• Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
  AIDS (London, England) 2015 Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV
• Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
  The New England journal of medicine 2010 Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S…
• Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children.
  Journal of acquired immune deficiency syndromes (1999) 2010 Weinberg A, Song LY, Walker R, Allende M, Fenton T, Patterson-Bartlett J, Nachman S, Kemble G, Yi TT, Defechereux P, Wara D, Read JS, Levin M, IMPAACT P1057 Team
• Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization.
  Clinical and vaccine immunology : CVI 2009 Weinberg A, Song LY, Wilkening C, Sevin A, Blais B, Louzao R, Stein D, Defechereux P, Durand D, Riedel E, Raftery N, Jesser R, Brown B, Keller MF, Dickover R, McFarland E, Fenton T, Pediatric ACTG …
• Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy.
  The Journal of infectious diseases 2005 Weinberg A, Gona P, Nachman SA, Defechereux P, Yogev R, Hughes W, Wara D, Spector SA, Read J, Elgie C, Cooper M, Dankner W, Pediatric AIDS Clinical Trials Group 1008 Team
• The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation.
  The EMBO journal 2001 Jordan A, Defechereux P, Verdin E